- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11.25 | Prostatype Genomics AB: Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics | 189 | GlobeNewswire (Europe) | Alongside Prostatype Genomics (the "Company") strategic focus on the U.S. market and continued efforts to secure Medicare reimbursement, the Company has continuously invested in research and development... ► Artikel lesen | |
| 26.08.25 | Prostatype Genomics AB: Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype to insurance companies in the USA | 171 | GlobeNewswire (Europe) | Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has reached an important commercial milestone in the USA by immediately starting to bill Prostatype® to several insurance companies. Prostatype®... ► Artikel lesen | |
| 23.07.25 | Prostatype Genomics AB: Prostatype Genomics publishes its interim report for the first half of 2025 | 200 | GlobeNewswire (Europe) | Prostatype Genomics AB today publishes its interim report for the first half of 2025. The full interim report is attached and can also be downloaded from the company's website, www.prostatypegenomics.com.
First... ► Artikel lesen | |
| 22.07.25 | Prostatype Genomics AB: Positive results for Prostatype confirmed in published Spanish multicentre study | 487 | GlobeNewswire (Europe) | Prostatype Genomics announces that previously communicated positive results from a Spanish multicentre study with Prostatype®, have now been confirmed in a scientific journal. The study included 93... ► Artikel lesen | |
| 03.06.25 | Prostatype Genomics AB: Strong results for Prostatype in published Taiwan study - creating opportunities for commercial expansion in Asia | 200 | GlobeNewswire (Europe) | Prostatype Genomics announces that strong results from a study in Taiwan with the company's prognostic genomic test Prostatype® have now been published in the scientific journal BJUI Compass. In the... ► Artikel lesen | |
| 15.05.25 | Prostatype Genomics AB: Prostatype Genomics updates on commercial progress in the U.S. | 267 | GlobeNewswire (Europe) | Prostatype Genomics announces that the company's commercial activities in the U.S. continue to develop in a positive way. The number of selected American urologists at urology clinics/hospitals who... ► Artikel lesen | |
| 15.05.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 15.05.2025 | 1.052 | Xetra Newsboard | Das Instrument B8D CH1107979838 R+S GROUP HOLDI CUM.PREF. EQUITY wird cum Kapitalmassnahme gehandelt am 15.05.2025 und ex Kapitalmassnahme am 16.05.2025 The instrument B8D CH1107979838 R+S GROUP HOLDI... ► Artikel lesen | |
| 15.04.25 | Prostatype Genomics AB: Prostatype Genomics AB resolves on a rights issue of units to fund completion of US validation study and Medicare approval process as well as ongoing commercialization activities in the US and Europe | 276 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA... ► Artikel lesen | |
| PROSTATYPE GENOMICS Aktie jetzt für 0€ handeln | |||||
| 10.04.25 | Prostatype Genomics AB: Prostatype Genomics newsletter highlights positive U.S. study results and increasing clinical use in Italy | 455 | GlobeNewswire (Europe) | This newsletter highlights two significant achievements: positive preliminary results in the U.S. study with Prostatype® conducted with leading U.S. institutions, and that the clinical use of Prostatype®... ► Artikel lesen | |
| 14.02.25 | Prostatype Genomics AB receives observation status | 388 | GlobeNewswire | On February 13, 2025, Prostatype Genomics AB (the "Company") disclosed its annual financial statement release for 2024 with information on the Company's financial situation.
The rules of Nasdaq... ► Artikel lesen | |
| 13.02.25 | Prostatype Genomics AB: Prostatype Genomics publishes year-end report for 2024 | 403 | GlobeNewswire (Europe) | Prostatype Genomics AB today publishes its year-end report for the full year 2024, including the interim report for the second half of 2024. The full year-end report is attached and can also be downloaded... ► Artikel lesen | |
| 13.02.25 | Prostatype Genomics AB: Prostatype Genomics submits supplementary answers in the final phase of its Medicare application for reimbursement in the United States | 263 | GlobeNewswire (Europe) | Prostatype Genomics AB announces that the company has compiled and submitted supplementary answers in the final phase of its Medicare application to get the prognostic genomic test Prostatype® approved... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 44,920 | +0,54 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum ersten Geschäftsquartal auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern... ► Artikel lesen | |
| ECKERT & ZIEGLER | 15,260 | -0,13 % | Morgen-Update: Eckert&Ziegler legt kräftig zu - jetzt reden alle über diesen Wert! | ||
| MOUNTAIN VALLEY MD | 0,007 | -37,50 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| CYTOSORBENTS | 0,608 | +5,56 % | Cytosorbents Corp: CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update | Third quarter 2025 revenue of $9.5 million, up 10% year-over-year
Amended credit agreement with Avenue Capital Group which strengthens our balance sheet... ► Artikel lesen | |
| MEDARTIS | 94,60 | -1,05 % | Adhoc: Medartis Holding AG: Medartis ernennt Peter Hackel zum neuen Finanzchef | Medartis Holding AG / Schlagwort(e): Personalie
Medartis ernennt Peter Hackel zum neuen Finanzchef 24.11.2025 / 06:59 CET/CEST
Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR
Für... ► Artikel lesen | |
| GESUNDHEITSWELT CHIEMGAU | 12,700 | 0,00 % | EQS-Adhoc: Gesundheitswelt Chiemgau AG: Anpassung der Prognose für das Geschäftsjahr 2025 | EQS-Ad-hoc: Gesundheitswelt Chiemgau AG / Schlagwort(e): Prognoseänderung
Gesundheitswelt Chiemgau: Anpassung der Prognose für das Geschäftsjahr 2025
20.10.2025 / 14:27 CET/CEST
Veröffentlichung... ► Artikel lesen |
Das Unternehmen PROSTATYPE GENOMICS AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,023 Euro und damit -1,72 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROSTATYPE GENOMICS AB finden Sie auf Wallstreet Online.